Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Beyond Progression in Platinum-Sensitive Ovarian Cancer
NCT01802749Phase 3Unknown
- Sponsor
- National Cancer Institute
- Start
- Nov 2013
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of bevacizumab in ovarian cancer, sponsored by National Cancer Institute. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01802749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802749.